FIELD: chemistry.
SUBSTANCE: present invention pertains to new compounds with formula (1): and to their pharmaceutical salts, where B, X, A or V are not present, if Z1, Z2, Z3 or Z4 respectively represent N, and independently H, halogen atom, azido, R2, CH2R2, SR2, OR2 or NR1R2, when Z1, Z2, Z3 or Z4 represent C. In each NR1R2, R1 and R2 together with N there can be formation of an optionally substituted piperidine, pyrrolidine, piperazine or morpholine ring. Z1 represents N and Z2, Z3 and Z4 represent C, or Z1 and Z3 represent N and Z2 and Z4 represent C. W together with N and Z form an optionally substituted thiazole, imidazole or pyrimidine ring, which is condensed with an optionally substituted ring, chosen from a group consisting of: or . U represents NR1R2, NR1-(CR1 2)n-NR3R4, where in NR3R4, R3 and R4 together with N there can be formation of an optionally substituted piperidine, pyrrolidine, piperazine or morpholine ring. R1 and R3 independently represent H or C1-6alkyl. Each R2 represents H or C1-10alkyl, each optionally substituted with a halogen atom, or C3-6cycloalkyl, aryl, heteroaryl or pyridine, pyrrolidine, piperazine or morpholine ring, where each ring is optionally substituted; or R2 is optionally substituted with piperidine, pyrrolidine, pyridine, piperazine, pyrazine, morpholine or benzimidazole. R2 represents H or C1-10alkyl. Each R5 represents a substitute in any position in ring W, and is H, OR2, amino, alkoxy, amido, halogen atom or cyano; or R5 represents C1-6alkyl, -CONHR1-, each optionally substituted with a halogen atom; or two adjacent R5 are linked with formation of a 5-6-member ring, an optionally substituted heterocyclic ring, chosen piperidine, pyrrolidine, piperazine or morpholine ring. n equals 1-6, and each optionally substituted part can be substituted with one or more halogens, OR2, NR1R2 , carbamate, C1-10alkyl, each optionally substituted with a halogen atom, C=O, cyano, nitro, COR2, NR2COR2, sulphonyl amides, NR2SOOR2; SR2, SOR2, COOR2, CONR2 2, OCOR2, OCOOR2 or OCONR2 2. The invention also relates to pharmaceutical compositions, to the method of suppressing proliferation of cells and/or weakening cell proliferative breakdown, to the method of reducing microbe titre and/or weakening microbe infection, to the method of inducing death of cells and/or inducing apoptosis, to compounds, chosen from a group, to pharmaceutical compositions, as well as to the method of producing compounds with formula (1).
EFFECT: obtaining new biologically active compounds, which can suppress proliferation of cells and/or induce apoptosis.
41 cl, 113 ex, 12 tbl
Title | Year | Author | Number |
---|---|---|---|
QUINOLONE ANALOGUES AND RELATED METHODS | 2008 |
|
RU2549895C2 |
SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | 2013 |
|
RU2681209C2 |
CASPASE INHIBITORS | 1999 |
|
RU2274642C2 |
INTERLEIKYN-1BETA CONVERTING ENZYME INHIBITORS | 1996 |
|
RU2249598C2 |
6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEINKINASE INHIBITORS | 2005 |
|
RU2379308C2 |
HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | 2012 |
|
RU2648997C2 |
LYSINE-SPECIFIC HISTONE DEMETHYLASE 1A (KDM1A) INHIBITORS FOR DISEASE THERAPY | 2019 |
|
RU2813145C2 |
COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
PYRAZINE DERIVATIVES USED AS ATR KINASE INHIBITORS | 2009 |
|
RU2604066C2 |
COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
Authors
Dates
2009-03-20—Published
2005-09-16—Filed